Abstract
Background: The human papillomavirus (HPV) vaccination program for young girls aged 11–26 years was introduced in Switzerland in 2008. The objective of this study was to evaluate the prevalence of high- and low-risk HPV in a population of undergraduate students using self-sampling for monitoring the HPV vaccination program’s effect. Methods: Undergraduate women aged between 18–31 years, attending the Medical School and University of Applied Sciences in Geneva, were invited to participate in the study. Included women were asked to perform vaginal self-sampling for HPV testing using a dry cotton swab. Results: A total of 409 students participated in the study—aged 18–31 years—of which 69% of the participants were vaccinated with Gardasil HPV vaccine and 31% did not received the vaccine. About HPV prevalence, 7.2% of unvaccinated women were HPV 16 or 18 positive, while 1.1% of vaccinated women were infected by HPV 16 or 18 (p < 0.01). Prevalence of HPV 6 and 11 was 8.3% in non-vaccinated women versus 2.1% in vaccinated women (p < 0.02). We observed no cross-protection for the other HPV genotypes of a low- and high-risk strain. Conclusions: Prevalence of HPV 6/11/16/18 was lower in vaccinated women versus unvaccinated women. Continued assessment of HPV vaccine effectiveness in real population is needed.
Highlights
IntroductionThe development of cervical precancerous and cancerous lesions is a direct consequence of genital human papillomavirus (HPV) infection, which has been identified as the most common sexually transmitted infection in the world [2]
Cervical cancer is one of the leading causes of cancer-related death among women worldwide [1].The development of cervical precancerous and cancerous lesions is a direct consequence of genital human papillomavirus (HPV) infection, which has been identified as the most common sexually transmitted infection in the world [2]
We observed no cross-protection for the other HPV genotypes of a low- and high-risk strain
Summary
The development of cervical precancerous and cancerous lesions is a direct consequence of genital human papillomavirus (HPV) infection, which has been identified as the most common sexually transmitted infection in the world [2]. Recent studies have predicted that cervical cancer rates will be drastically reduced in about 10–15 years, thanks to the impact of the HPV vaccination and HPV-based screening [4]. Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for. The human papillomavirus (HPV) vaccination program for young girls aged. The objective of this study was to evaluate the prevalence of high- and low-risk HPV in a population of undergraduate students using self-sampling for monitoring the HPV vaccination program’s effect. Methods: Undergraduate women aged between 18–31 years, attending the Medical School and University of Applied Sciences in Geneva, were invited to participate in the study. About HPV prevalence, 7.2% of unvaccinated women were HPV 16 or 18 positive, while 1.1% of vaccinated women were infected by HPV 16 or 18 (p < 0.01)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Environmental Research and Public Health
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
